Document:

Document

Exhibit 10.1

AMENDMENT NO. 2 
TO
AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN
OF NUVASIVE, INC.

WHEREAS, effective as of August 9, 2022 the Board of Directors of NuVasive, Inc. agreed to amend the Amended and Restated 2004 Employee Stock Purchase Plan, as amended from time to time (the “AR 2004 ESPP”), pursuant to Section 26 of the AR 2004 ESPP.

NOW, THEREFORE, the AR 2004 ESPP shall be amended as of August 9, 2022 as follows:

1.The last sentence of Section 22 of the AR 2004 ESPP is amended in its entirety to read as follows:

“This Plan shall continue until the earlier to occur of (a) termination of this Plan by the Board or the Committee (which termination may be effected by the Board or the Committee at any time), (b) issuance of all the shares of Common Stock reserved for issuance under this Plan, or (c) December 31, 2026.”

2.Except as amended by this Amendment No. 2, the AR 2004 ESP shall remain unchanged and in full force and effect.

3.Except as otherwise provided in this Amendment No. 2, terms used herein shall have the meanings ascribed to such terms in the AR 2004 ESPP.Document

Exhibit 10.2

August 22, 2022

Michael Farrington

Dear Mike, 
Congratulations on your new full-time, exempt role of Senior Vice President, People and Culture, with NuVasive, Inc. at our San Diego, California site.  Our Company’s continued success is dependent on employees like you embodying our core values and working diligently to drive our priorities.  In this new role, you will report to me, and we would like for you to begin your role in this capacity on September 5, 2022.
I am pleased to present you with changes to your compensation package as detailed below.
JOB TITLE, CAREER BAND & COMPENSATION
Job Title:  Senior Vice President, People and Culture
Career Band:  P12
Target Direct Compensation Package:
												
		Current	New	Change
	Annual Salary Rate
(Next Salary Review Q1 2023)
	$325,000	$350,000	+7.7%
	Annual Bonus Target %*
(Anticipated to be effective September 5, 2022)
	$195,000 (60%)	$210,000 (60%)	+7.7%
	Annual LTI Target	$400,000	$500,000	+25%
				
	Annual Target Total Direct Compensation:	$920,000	$1,060,000	+15.2%

* Above table is for illustrative purposes only. You will continue to be eligible for the discretionary annual corporate bonus plan which depends upon the Company’s successful achievement of its operational goals and your overall performance against your goals. This bonus requires that you be employed in good standing on the payout date (which is generally the first week of March, in the following year). Bonus target percentage changes after April 1 of the plan year are adjusted to account for changes during the plan year.  Your Bonus Target amount shall equal the sum of your Eligible Earnings for the period of time in role multiplied by the respective Target Bonus Percentage for each bonus-eligible role you occupied during the plan year.

As outlined in the table above, we expect to provide you with a 2023 annual LTI award that has a grant face value of USD $500,000, which is expected to be made in March 2023.  This award is expected to be comprised of restricted stock units and performance stock units, consistent with the annual LTI awards for other Company executives, and subject to cliff vesting on the third anniversary of the date of grant.  The value and form of award is subject to approval by NuVasive’s Board of Directors or its delegate and will be governed by the terms of the applicable grant agreements(s).
In your new role, you will continue to be eligible for NuVasive’s executive benefits package, which currently includes an annual executive physical, executive financial planning and eligibility to participate in a deferred compensation plan.  Further, you will be eligible for benefits under the NuVasive Executive Severance Plan, in accordance with the terms thereof.  Also, subject to approval by NuVasive’s Board of Directors or its delegate, you will be eligible to receive an individual Change-in-Control Agreement with a cash severance multiplier of 1.5x, and which still requires a “double-trigger” of events before any respective severance benefits are payable.

Your employment with NuVasive remains “at-will.”  This means your employment is not for any specified period of time and can be terminated by you or NuVasive at any time for any reason, with or without cause or advance notice.  As a Company employee, you will be required to comply with all Company policies and procedures.  You will also be subject to NuVasive’s stock ownership guidelines, which require that you acquire and maintain ownership of NuVasive stock with a value equal to one times (1x) your base salary within five years, subject to and in accordance with the terms of the guidelines.  
I look forward to your continued dedication to driving our purpose and priorities as we continue to build the future of NuVasive together. If you have any questions regarding your compensation, please don’t hesitate to reach out to me or your HR representative.
Sincerely,
 /s/ J. Christopher Barry
Chris Barry
Chief Executive Officer

I have read this offer letter in its entirety and agree with the terms and conditions of employment.  I understand and agree that my employment with NuVasive is at-will.
									
	8/23/22		/s/ Michael Farrington

	Dated		Michael Farringtonexhibit_41x20220930

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR  UNDER THE SECURITIES LAWS OF ANY STATE.  THESE SECURITIES MAY NOT BE  OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED  EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE  SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION  REQUIREMENTS OR AN EXEMPTION THEREFROM.  THE ISSUER OF THIS WARRANT  MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE  ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION  OTHERWISE COMPLIES WITH THE SECURITIES ACT AND ANY APPLICABLE STATE  SECURITIES LAWS.  THIS WARRANT MUST BE SURRENDERED TO THE COMPANY  OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER,  PLEDGE OR HYPOTHECATION OF THIS WARRANT OR ANY OF THE UNDERLYING  SECURITIES REPRESENTED HEREBY.  AMENDED AND RESTATED WARRANT  CENTRUS ENERGY CORP.  WARRANT TO PURCHASE COMMON STOCK  To Purchase 250,000 Shares of Class A Common Stock,  Par Value $0.10 Per Share  Date of Issuance:  October 17, 2022  VOID AFTER February 5, 2023  THIS CERTIFIES THAT, pursuant to this Amended and Restated Warrant (this  “Warrant”), for value received, Kulayba LLC, or permitted registered assigns (the “Holder”), is  entitled, subject to the terms and conditions set forth herein, to subscribe for and purchase at the  Exercise Price (as defined below) from Centrus Energy Corp., a Delaware corporation (the  “Company”), 250,000 shares of Class A Common Stock, par value $0.10 per share (the  “Common Stock”) of the Company.  For good and valuable consideration received, the Holder  and the Company each acknowledge and agree that this Amended and Restated Warrant replaces  that certain Warrant dated February 5, 2021 between the Holder and the Company (the  “Original Warrant”).  By accepting this Warrant, the Holder hereby agrees to surrender to the  Company for cancellation the Original Warrant or, at the request of the Company, to execute an  instrument of cancellation in form and substance acceptable to the Company. The Holder and the  Company hereby acknowledge and agree that upon the issuance of this Warrant, the Original  Warrant shall be amended and restated and all of the Company’s obligations under such Original  Warrant shall be discharged and released in full without any further action on the part of the  Company or the Holder.  

 

2  1. DEFINITIONS.  As used herein, the following terms shall have the following  respective meanings:  (a) “Business Day” shall mean any day that is not a Saturday, Sunday or other day on  which commercial banks in New York City are authorized or required by law to remain closed.  (b) “Exercise Period” shall mean the period commencing with the date hereof and  ending, unless sooner terminated as provided below, on the first to occur of:  (a) the second  anniversary of the date hereof or (b) the last Business Day immediately prior to the  consummation of a Fundamental Transaction (as defined below) which results in the  shareholders of the Company immediately prior to such Fundamental Transaction owning less  than 50% of the voting equity of the surviving entity immediately after the consummation of the  Fundamental Transaction.  (c) “Exercise Price” shall mean $21.62 per share, subject to adjustment pursuant to  Section 5 below.  (d) “Exercise Shares” shall mean the shares of Common Stock issuable upon exercise of  this Warrant.  (e) “ Fundamental Transaction” shall mean the occurrence of any of the following at  any time while this Warrant is outstanding:  (i) the Company effects any merger or consolidation  of the Company with or into another entity, in which the shareholders of the Company as of  immediately prior to the transaction own less than a majority of the outstanding stock of the  surviving entity, (ii) the Company effects any sale of all or substantially all of its assets in one or  a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company  or another person or entity) is completed pursuant to which holders of Common Stock are  permitted to tender or exchange their shares for other securities, cash or property, or (iv) the  Company effects any reclassification of the Common Stock or any compulsory share exchange  pursuant to which the Common Stock is effectively converted into or exchanged for other  securities, cash or property (other than as a result of a subdivision or combination of shares of  Common Stock covered by Section 5 below).  (f) “Market Price” means, as to any security, the closing price for such security on the  principal domestic securities exchange on which such security is listed, or, if there have been no  sales on such exchange on any day, the average of the highest bid and lowest asked prices on  such exchange at the end of such day, or, if on any day such security is not so listed, the average  of the highest bid and lowest asked prices on such day in the domestic over-the-counter market  as reported by OTC Markets Group, or any similar successor organization; provided that if such  security is listed on any domestic securities exchange the term “business days” as used in this  sentence means business days on which such exchange is open for trading. If at any time such  security is not listed on any domestic securities exchange or quoted in the domestic over-the- counter market, the “Market Price” shall be determined in good faith by the Board of Directors  of the Company.  2. EXERCISE OF WARRANT.  The rights represented by this Warrant may be  exercised in whole at any time during the Exercise Period by delivery of the following to the  

 

3  Company at its address set forth on the signature page hereto (or at such other address as it may  designate by notice in writing to the Holder):  (a) An executed notice of exercise in the form attached hereto (the “Notice of  Exercise”);  (b) Payment of the Exercise Price either in cash or by check; and  (c) This Warrant for cancellation.  As an alternative to the exercise of this Warrant by payment the Exercise Price as  provided above, the Holder may elect to exchange all or part of the purchase rights represented  by this Warrant by surrendering this Warrant to the Company, together with a written notice to  the Company that the holder is exchanging the Warrant (or a portion thereof) for an aggregate  number of shares of Common Stock specified in the Notice of Exercise, from which the  Company shall withhold and not issue to the holder a number of shares of Common Stock with  an aggregate Market Price equal to the Exercise Price for the number of shares of Warrant Stock  specified in such notice (and such withheld shares shall no longer be issuable under this  Warrant). The exercise of the option described in this paragraph is referred to as a “Cashless  Exercise.”  The Company shall deliver any objection to any Notice of Exercise within two (2)  Business Days of receipt of such notice.  In the event of any discrepancy or dispute, the records  of the Company shall be controlling and determinative in the absence of manifest error.  Certificates for shares purchased hereunder shall be transmitted by the transfer agent of  the Company to the Holder by crediting the account of the Holder’s prime broker with the  Depository Trust Company (“DTC”) through its Deposits and Withdrawal at Custodian  (DWAC) system if the Company is a participant in such system, or otherwise through book-entry  recordation by the Company’s transfer agent, or physical delivery to the address specified by the  Holder in the Notice of Exercise as soon as practicable after the delivery to the Company of the  Notice of Exercise (the “Share Delivery Date”), the surrender of this Warrant and the payment  of the aggregate Exercise Price as set forth above.  This Warrant shall be deemed to have been  exercised on the date the Exercise Price is received by the Company (or, in the case of Cashless  Exercise, the date the Company receives the Notice of Exercise in respect of such Cashless  Exercise).  The Exercise Shares shall be deemed to have been issued, and Holder or any other  person so designated to be named therein shall be deemed to have become a holder of record of  such shares for all purposes, as of the date this Warrant has been exercised by payment to the  Company of the Exercise Price and surrender of this Warrant by the Holder, irrespective of the  date of delivery of the Exercise Shares, except that, if the date of such surrender and payment is a  date when the stock transfer books of the Company are closed, such person shall be deemed to  have become the holder of such shares at the close of business on the next succeeding date on  which the stock transfer books are open.  3. COVENANTS OF THE COMPANY.  3.1 COVENANTS AS TO EXERCISE SHARES.  

 

4  (a) The Company covenants and agrees that all Exercise Shares that may be issued upon  the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and  outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect  to the issuance thereof.  (b) The Company further covenants and agrees that the Company will at all times during  the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient  number of shares of Common Stock to provide for the exercise of the rights represented by this  Warrant.  If at any time during the Exercise Period the number of authorized but unissued shares  of Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will  take such corporate action as may, in the opinion of its counsel, be necessary to increase its  authorized but unissued shares of Common Stock to such number of shares as shall be sufficient  for such purposes.  3.2 NOTICES OF RECORD DATE AND CERTAIN OTHER EVENTS.  In the event  of any taking by the Company of a record of the holders of any class of securities for the purpose  of determining the holders thereof who are entitled to receive any dividend or other distribution,  the Company shall mail to the Holder, at least ten (10) days prior to the date on which any such  record is to be taken for the purpose of such dividend or distribution, a notice specifying such  date.  In the event of any voluntary dissolution, liquidation or winding up of the Company, the  Company shall mail to the Holder, at least ten (10) days prior to the date of the occurrence of any  such event, a notice specifying such date.  In the event the Company authorizes or approves,  enters into any agreement contemplating, or solicits stockholder approval for any Fundamental  Transaction, as defined in Section 1 herein, the Company shall mail to the Holder, at least ten  (10) days prior to the date of the occurrence of such event, a notice specifying such date.  4. COVENANTS OF THE HOLDER.  4.1 AUTHORIZATION.  The Holder hereby represents and warrants that it has full  power and authority to enter into this Warrant and such Warrant constitutes its valid and legally  binding obligations, enforceable in accordance with its terms.  4.2 PURCHASE FOR OWN ACCOUNT.  The Holder acknowledges that this Warrant  is issued to the Holder in reliance upon the Holder’s representation to the Company, which by  the Holder’s execution of this Warrant the Holder hereby confirms, that this Warrant and the  Exercise Shares (collectively, the “Securities”) will be acquired for investment for the Holder’s  own account, not as a nominee or agent, and not with a view to the resale or distribution of any  part thereof, and that the Holder has no present intention of selling, granting any participation in  or otherwise distributing the same.  By executing this Warrant, the Holder represents that it does  not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or  grant participations to such person or to any third person, with respect to any of the Securities.   The Holder also represents that it has not been organized for the specific purpose of acquiring the  Securities.  4.3 DISCLOSURE OF INFORMATION.  The Holder acknowledges that it has received  all of the information it considers necessary or appropriate for deciding whether to purchase the  Securities.  The Holder further represents that it has had an opportunity to ask questions and  

 

5  receive answers from the Company regarding the terms and conditions of this Warrant and the  business, properties, prospects and financial condition of the Company.  4.4 INVESTMENT EXPERIENCE.  The Holder hereby represents and warrants that it  is an investor in securities of companies and acknowledges that it can bear the economic risk of  its investment, and has such knowledge and experience in financial or business matters that it is  capable of evaluating the merits and risks of the investment in the Securities.  4.5 ACCREDITED INVESTOR.  The Holder hereby represents and warrants that it is  an “accredited investor” within the meaning of the Securities and Exchange Commission  (“SEC”) Rule 501 of Regulation D, as presently in effect.  4.6 RESTRICTED SECURITIES.  (a) The Holder understands and acknowledges that the Securities are characterized as  “restricted securities” under the federal securities laws inasmuch as they are being acquired from  the Company in a transaction not involving a public offering and that under such laws and  applicable regulations such Securities may be resold without registration under the Securities Act  only in certain limited circumstances.  In the absence of an effective registration statement  covering the Securities or an available exemption from registration under the Securities Act, the  Securities must be held indefinitely.  The Holder represents that it is familiar with SEC Rule 144  (“Rule 144”) as presently in effect and understands the resale limitations imposed thereby and by  the Securities Act.  (b) The Exercise Shares shall be stamped or imprinted with a legend substantially similar  to the following (in addition to any legend required by state securities laws):  THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN  REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE  “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.   THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE  TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS  PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES  LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION  REQUIREMENTS OR AN EXEMPTION THEREFROM.  THE ISSUER OF  THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL  REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER,  SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE  COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES  LAWS.  THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY  OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE,  TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY  OF THE SECURITIES REPRESENTED HEREBY.  (c) The Holder covenants that in no event will the Holder dispose of any of the Securities  other than in conjunction with an effective registration statement for the Securities under the  Securities Act or in compliance with Rule 144 unless and until (i)(A) the Holder shall have  

 

6  notified the Company of the proposed disposition and shall have furnished the Company with a  statement of the circumstances surrounding the proposed disposition and (B) the Holder shall  have furnished the Company with an opinion of counsel satisfactory in form and substance to the  Company to the effect that (x) such disposition will not require registration under the Securities  Act and (y) appropriate action necessary for compliance with the Securities Act and any other  applicable state, local or foreign law has been taken or (ii) the Company shall have received a  letter secured by the Holder from the SEC stating that no action will be recommended to the SEC  with respect to the proposed disposition.  5. ADJUSTMENT OF EXERCISE PRICE AND SHARES.  (a) In the event of changes in the outstanding Common Stock of the Company by reason  of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchange of  shares, separations, reorganizations, liquidations, consolidation, acquisition of the Company  (whether through merger or acquisition of substantially all the assets or stock of the Company),  or the like, the number, class and type of shares available under this Warrant in the aggregate and  the Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on  exercise for the same aggregate Exercise Price, the total number, class, and type of shares or  other property as the Holder would have owned had this Warrant been exercised prior to the  event and had the Holder continued to hold such shares until the event requiring adjustment.  The  form of this Warrant need not be changed because of any adjustment in the number of Exercise  Shares subject to this Warrant.  (b) If at any time or from time to time the holders of Common Stock of the Company (or  any shares of stock or other securities at the time receivable upon the exercise of this Warrant)  shall have received or become entitled to receive, without payment therefor,  (i) Common Stock or any shares of stock or other securities which are at any  time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or  options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend  or other distribution (other than a dividend or distribution covered in Section 5(a) above);  (ii) any cash paid or payable otherwise than as a cash dividend; or  (iii) Common Stock or additional stock or other securities or property (including  cash) by way of spinoff, split-up, reclassification, combination of shares or similar corporate  rearrangement (other than shares of Common Stock pursuant to Section 5(a) above),  then and in each such case, the Holder hereof will, upon the exercise of this  Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable  thereupon, and without payment of any additional consideration therefor, the amount of stock  and other securities and property (including cash in the cases referred to in clauses (ii) and (iii)  above) which such Holder would hold on the date of such exercise had such Holder been the  holder of record of such Common Stock as of the date on which holders of Common Stock  received or became entitled to receive such shares or all other additional stock and other  securities and property.  

 

7  (c) Upon the occurrence of each adjustment pursuant to this Section 5, the Company at  its expense will, at the written request of the Holder, promptly compute such adjustment in  accordance with the terms of this Warrant and prepare a certificate describing the transactions  giving rise to and setting forth in reasonable detail the calculation of such adjustment, including a  statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares or other  securities issuable upon exercise of this Warrant (as applicable).  The Company will promptly  deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.  6. FRACTIONAL SHARES.  No fractional shares shall be issued upon the exercise of  this Warrant as a consequence of any adjustment pursuant hereto.  All Exercise Shares (including  fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining  whether the exercise would result in the issuance of any fractional share.  If, after aggregation,  the exercise would result in the issuance of a fractional share, the Company shall, at its election,  either pay the Holder otherwise entitled to such fraction a sum in cash equal to the product  resulting from multiplying the then current fair market value of an Exercise Share by such  fraction or the number of Exercise Shares to be issued shall be rounded up or down, as  applicable, to the nearest whole number.  7. NO STOCKHOLDER RIGHTS.  Other than as provided in Section 3.2 or  otherwise herein, this Warrant in and of itself shall not entitle the Holder to any voting rights or  other rights as a stockholder of the Company.  8. TRANSFER OF WARRANT.  Subject to compliance with any applicable laws, this  Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized  attorney, upon delivery of this Warrant and the form of assignment attached hereto to any  transferee designated by Holder.  The transferee shall sign an investment letter in form and  substance reasonably satisfactory to the Company and its counsel.  9. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT.  If this Warrant  is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or  otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include  the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so  lost, stolen, mutilated or destroyed.  Any such new Warrant shall constitute an original  contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or  destroyed Warrant shall be at any time enforceable by anyone.  10. NOTICES, ETC.  All notices required or permitted hereunder shall be in writing and  shall be deemed effectively given:  (a) upon personal delivery to the party to be notified, (b)  when sent by confirmed email or facsimile if sent during normal business hours of the recipient,  if not, then on the next Business Day, (c) five days after having been sent by registered or  certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a  nationally recognized overnight courier, specifying next day delivery, with written verification of  

 

8  receipt.  All communications shall be sent to the Company at the address listed on the signature  page hereto, with a copy to:  O’Melveny & Myers LLP  Two Embarcadero Center, 28th Floor  San Francisco, CA 9411-3823  Attention:  C. Brophy Christensen  Email:  bchristensen@omm.com  Facsimile No.:  (415) 984-8701  Attention:  Eric Sibbitt  Email:  esibbitt@omm.com  Facsimile No.:  (415) 984-8701  and to Holder at:  15 Ocean Avenue  Brooklyn, NY 11225  Email:  morris@bawabeh.com  or at such other address as the Company or Holder may designate by ten (10) days advance  written notice to the other parties hereto, with a copy to:  Breslow & Walker, LLP  100 Jericho Quadrangle, Suite 230  Jericho, NY 11753  Attention:  Len Breslow, Esq.  Email:  lbreslow@breslowwalker.com  Facsimile No.:  (516) 822-6544  11. ACCEPTANCE.  Receipt of this Warrant by the Holder shall constitute acceptance  of and agreement to all of the terms and conditions contained herein.  12. GOVERNING LAW.  This Warrant shall be governed by, and construed in  accordance with, the laws of the State of New York.  The Holder hereby submits to the non- exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of  New York in any suit or proceeding arising out of or relating to this Agreement or the  transactions contemplated thereby.  The Holder irrevocably and unconditionally waives any  objection to the laying of venue of any suit or proceeding arising out of or relating to this  Warrant in Federal and state courts in the Borough of Manhattan in The City of New York and  irrevocably and unconditionally waives and agrees not to plead or claim in any such court that  any such suit or proceeding in any such court has been brought in an inconvenient forum.  13. AMENDMENT OR WAIVER.  Any term of this Warrant may be amended or  waived (either generally or in a particular instance and either retroactively or prospectively) with  the written consent of the Company and the Holder.  No waivers of any term, condition or  

 

9  provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a  further or continuing waiver of any such term, condition or provision.  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]     

 

10  IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its  duly authorized officer as of October 17, 2022.  CENTRUS ENERGY CORP.  By:   Name:  Philip Strawbridge  Title:    Senior Vice President, Chief Financial  Officer, Chief Administrative Officer, and  Treasurer  Centrus Energy Corp.  6901 Rockledge Drive, Suite 800  Bethesda, Maryland 20817  Attention:  Dennis Scott  Email: scottd@centrusenergy.com  Facsimile No.:  (605) 696-7250  

 

11  NOTICE OF EXERCISE  TO:  CENTRUS ENERGY CORP.  (1) [CHECK ONE]  [   ] The undersigned hereby elects to purchase 250,000 shares of the Class A Common  Stock, par value $0.10 (the “Common Stock”), of CENTRUS ENERGY CORP. (the  “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the  exercise price in full, together with all applicable transfer taxes, if any.  [   ] The undersigned hereby elects to purchase 250,000 shares of Common Stock of the  Company pursuant to the terms of the attached Warrant, pursuant to Cashless Exercise (as  defined in the Warrant).  (2) Please issue the certificate for shares of Common Stock in the name of, and pay any  cash for any fractional share to:  Print or type name     Social Security or other Identifying Number  Street Address     City State Zip Code     (Signature)     (Print Name)     (Date)     

 

12  ASSIGNMENT FORM  (To assign the foregoing Warrant, execute this form and supply required information.  Do  not use this form to purchase shares.)  FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are  hereby assigned to  Name:    (Please Print)  Address:    (Please Print)  Dated: , 202__     Holder’s Signature:    Holder’s Address:    NOTE:  The signature to this Assignment Form must correspond with the name as it appears on  the face of the Warrant, without alteration or enlargement or any change whatever.  Officers of  corporations and those acting in a fiduciary or other representative capacity should file proper  evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]